Axsome Therapeutics’ AXSM shares have rallied 19.4% in the past month against the industry’s decrease of 0.2%, driven by investor enthusiasm about the company’s encouraging preliminary sales numbers ...

Ascentage Pharma Group (AAPG) (AAPGV) (ASPHF), which is backed by Takeda (TAK), has priced a $126M U.S. initial public offering. Read more here.

Minot Light Capital, an investment management firm, recently released its fourth-quarter 2024 investor letter. A copy of the ...

H.C. Wainwright's valuation of Microbot Medical (NASDAQ:MBOT) stands at an estimated market value of $255 million, or $9 per share, which underpins the revised price target. The current market ...

The firm's positive outlook is also based on Eton's consistent year-over-year revenue growth, with current revenues at $34.68 million and an impressive gross margin of 59.3%. H.C. Wainwright forecasts ...

JMP Securities analyst reaffirmed a positive outlook on Larimar Therapeutics (NASDAQ:LRMR), maintaining a Market Outperform ...

Generally, you can count on drugmakers for a steady revenue performance -- since patients need their medicines, revenue holds ...

Carl's away, so I've punched out a bite-sized Evening Wrap ASX 200 ticked higher and finished the week up 1.19% Wesfarmers ...

Morgans analyst Scott Power says there's been a rotation back into small healthcare stocks as EBR Systems records a massive ... Read More The post Scott Power: Cardiac pacing device developer EBR hits ...

Altimmune, Inc. (NASDAQ:ALT), a biopharmaceutical company with a market capitalization of $503.56 million focused on ...

As the percentage of the global population over 65 continues to increase, the popularity of anti-aging stocks is rising in ...

Following a filing revealing its intent to go public in the US on 6 January, artificial pancreas maker Beta Bionics has now ...